# Lymphangioleiomyomatosis and Cystic Lung Diseases

> Lymphangioleiomyomatosis for NEET-PG Medicine covers the HRCT cyst pattern, tuberous sclerosis link, chylous effusion, pneumothorax and sirolimus therapy.

- Canonical URL: https://prepelephant.com/topics/neet-pg/medicine/lymphangioleiomyomatosis-and-cystic-lung-diseases
- Exam / course: NEET-PG · Subject: Medicine
- Publisher: PrepElephant (https://prepelephant.com) — Prepared and reviewed by the PrepElephant Academic Review Team
- First published: 2026-10-14
- Last updated: 2026-10-14
- Reference basis: Harrison's Principles of Internal Medicine; Murray and Nadel's Textbook of Respiratory Medicine
- How to cite: "Lymphangioleiomyomatosis and Cystic Lung Diseases", PrepElephant, https://prepelephant.com/topics/neet-pg/medicine/lymphangioleiomyomatosis-and-cystic-lung-diseases

## Direct answer

Lymphangioleiomyomatosis (LAM) is a rare, progressive cystic lung disease of women of reproductive age, caused by abnormal proliferation of smooth-muscle-like LAM cells. High-resolution CT shows numerous uniform, thin-walled cysts spread through both lungs with normal tissue between them, and the picture includes progressive breathlessness, recurrent pneumothorax and chylous effusion. Sirolimus, an mTOR inhibitor, is the drug that slows the loss of lung function.

## What you must remember

- **Who gets it:** almost exclusively women of reproductive age, and oestrogen exposure, including pregnancy, can worsen the disease.
- **Sporadic or syndromic:** LAM occurs sporadically or with tuberous sclerosis complex, where TSC1 or TSC2 mutations are found.
- **HRCT pattern:** diffuse, thin-walled, regular cysts with preserved lung between them, unlike the irregular bullae of emphysema.
- **Serum VEGF-D:** a raised level supports the diagnosis, and lung biopsy is reserved for uncertain cases.
- **Chylous complications:** chylothorax and chylous ascites arise from lymphatic obstruction by lymphangiomyomas.
- **Pneumothorax:** recurrent spontaneous pneumothorax is a common presenting feature and often prompts the first diagnosis.
- **Definitive care:** sirolimus stabilises lung function, and lung transplantation is reserved for end-stage failure.

## A stepwise approach from suspicion to treatment

A 31-year-old woman has three years of exertional breathlessness and a second right-sided pneumothorax. Her chest radiograph shows fine reticular change, so the task is to separate LAM from emphysema and interstitial disease.

1. **Think of LAM in young women:** progressive breathlessness with recurrent pneumothorax or chylous effusion should prompt HRCT rather than a routine label of emphysema.
2. **Read the HRCT pattern:** numerous uniform, thin-walled cysts through both lungs, with preserved intervening parenchyma, point strongly towards LAM.
3. **Look for tuberous sclerosis:** check for facial angiofibromas, ash-leaf macules, renal angiomyolipomas and cardiac rhabdomyomas, and consider TSC genetic testing.
4. **Measure the baseline:** spirometry, lung volumes and diffusing capacity usually show obstruction with reduced DLCO, giving a reference for later comparison.
5. **Treat the complications:** a chest drain or pleurodesis manages pneumothorax, and dietary fat restriction with medium-chain triglycerides is commonly used for chylous effusion.
6. **Start sirolimus or refer:** sirolimus is offered for progressive disease with monitoring for side effects such as hyperlipidaemia, and transplant referral follows severe failure.

## Where the exam tries to catch you

Most lost marks come from mislabelling the cyst pattern or choosing the wrong drug class.

- **Trap:** calling the cysts emphysema because the patient is a smoker — **Correct:** LAM is not a smoking disease, and its cysts are uniform and thin-walled rather than irregular bullae.
- **Trap:** treating the disease with bronchodilators or steroids — **Correct:** sirolimus targets the mTOR pathway, whereas bronchodilators only relieve symptoms.
- **Trap:** assuming a chylous effusion signals malignancy — **Correct:** in LAM it reflects lymphatic obstruction, and the HRCT pattern with the clinical picture settles the diagnosis.
- **Trap:** prescribing oestrogen-containing contraception without thought — **Correct:** hormonal exposure may worsen disease, so the choice is individualised with a specialist.

## Frequently asked questions

### Which HRCT finding makes lymphangioleiomyomatosis likely?

Diffuse, uniformly thin-walled cysts spread through both lungs, with normal intervening parenchyma, make lymphangioleiomyomatosis likely. This differs from emphysema, which shows irregular bullae, and from Langerhans cell histiocytosis, which shows nodules and cysts with relative upper-zone predominance.

### Which drug slows lung function decline in lymphangioleiomyomatosis?

Sirolimus, an mTOR inhibitor, is the drug used to slow lung function decline in lymphangioleiomyomatosis. It acts on the pathway that drives proliferation of LAM cells, and patients are monitored for hyperlipidaemia and other adverse effects.

### How is lymphangioleiomyomatosis linked to tuberous sclerosis complex?

Lymphangioleiomyomatosis occurs sporadically or as part of tuberous sclerosis complex, where TSC1 or TSC2 mutations are found. Clinicians therefore look for skin and renal features of TSC, such as angiofibromas and angiomyolipomas, in every patient with lymphangioleiomyomatosis.

### Why does chylous effusion matter in lymphangioleiomyomatosis?

Chylothorax and chylous ascites in lymphangioleiomyomatosis result from lymphatic obstruction by lymphangiomyomas. They signal lymphatic involvement, and management includes dietary fat restriction with medium-chain triglycerides under specialist review.

### Which tests help distinguish lymphangioleiomyomatosis from emphysema?

HRCT pattern, serum VEGF-D and the clinical profile separate lymphangioleiomyomatosis from emphysema. Emphysema is linked to smoking and shows irregular bullae, whereas lymphangioleiomyomatosis shows uniform cysts in young women who usually do not smoke.